Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Ronco succeeds Dr. Christine Dingivan, who will now serve as a senior advisor to Executive Chairman Sastry Chilukuri
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
